Close menu

 

Member of Lyonbiopole

 

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses.

 

Strategic application domain: Human Medicine

Application market: Infectious Diseases, Pneumology - Respiratory Diseases

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Vaccine

Created on may 16th, 2017 - 28 employees

 

Address

70 rue saint Jean de Dieu 69007 Lyon

 

Contacts

You must be logged in and a member of Lyonbiopôle to see the contacts.